September is World Alzheimer’s Month, and the global Alzheimer’s disease community is looking to raise awareness and combat ...

An experimental oral therapy called blarcamesine appears to slow the progression of Alzheimer’s disease, reducing the rate of cognitive decline and preserving daily function over the long term, ...

The FDA has approved Leqembi Iqlik, a subcutaneous, autoinjector formulation for maintenance dosing in people with early Alzheimer's disease ...

Alzheimer’s disease affects every aspect of a person’s being, altering personality and behaviors. A loved one diagnosed with dementia may behave irrationally or rudely toward family members, ...

Alzheimer’s disease (AD) is associated with a gradual decline in memory and mental ability, due to the accumulation and spread of damage in the brain. It is an irreversible condition, with symptoms ...

Treatment with lecanemab (BAN2401), an experimental amyloid-targeting antibody, significantly slowed the progression of dementia symptoms among people with early Alzheimer’s disease in the Phase 3 ...

Mental health is an issue that continues to raise concern in the United States. According to an annual report by the nonprofit organization Mental Health America, incidences of anxiety and depression ...

Foralumab, an investigational nasal spray being developed by Tiziana Life Sciences, has been cleared by the U.S. Food and Drug Administration (FDA) for expanded use to treat moderate Alzheimer’s ...

Nearly half of Alzheimer’s disease patients treated with TrueBinding’s investigational therapy TB006 for at least three months showed signs of disease reversal or cognitive improvement, according to ...

Blazing through a magazine or newspaper is an activity most of us take for granted. However, someone with cognitive impairment may have difficulty devouring content. Deciphering small print and ...

When Lewis Hornby’s grandmother was rushed to the hospital in 2018, his family feared the worst. Pat Dickinson suffered from dementia, but in this instance it turned out that she was simply dehydrated ...

Cognitive benefits were reported in nearly half of the Alzheimer’s disease patients given simufilam for one year in a clinical trial, while those with early-stage, mild disease appeared to respond ...